The Sheep Veterinary Society and Flock Health Clubs have announced a series of free fortnightly 45-minute CPD webinars for vets looking to engage more productively with their sheep farmer clients and update their understanding of flock economics.

‘Sheep Vets - Fit for the Future’ are being presented by well-respected industry leaders, vets and sheep farmers on Tuesday evenings during May, June and July.

Webinar organiser, Dr Fiona Lovatt from Flock Health Limited (pictured right) said: "We are optimistic about the future for the UK sheep industry, but to grasp the opportunities farmers need proactive vets who can demonstrate an added value approach. As vets we must think more holistically about the challenges sheep farmers face and that means optimising our understanding of how flock health issues, soil and grassland management, and environmental factors all link together with the economics. 

"This webinar programme aims to help keen sheep vets consider how they can best engage with their sheep farmer clients."

The first webinar in the series was attended by more than 100 delegates, and is now available as a recording. It highlighted the current state of the UK sheep industry and what the future 10 years might look like. 

Future topics include how to improve engagement with sheep farmers (26th May), how vets can best ensure successful lamb growth (9th June), understanding sheep farming economics (23rd June) and exploring the veterinary possibilities arising from different sources of flock data (7th July). Watch live at 7.30pm or catch up later with the recording.

Register for free by visiting www.sheepvetsoc.org.uk or www.flockhealth.co.uk

In contrast to the British Veterinary Association, The National Office of Animal Health (NOAH) has welcomed the decision by DEFRA not to proceed with the proposal contained in the draft Veterinary Medicines Regulations 2010 to prohibit the advertising of antimicrobials to farmers.

NOAH says it believes the proposal would have had a negative effect on farmers' ability to maintain their knowledge and awareness of animal health and welfare issues, and did not believe that it would reduce antimicrobial resistance profiles.

NOAH chief executive Phil Sketchley said: "Farmers, as professional producers of food, need to be kept well briefed on the antimicrobials they use, following prescription by their veterinary surgeons. Promotion by our members plays a key role in this and in educating farmers about animal welfare and disease."

NOAH members follow rigid rules on advertising and promotion through the longstanding Code of Practice for the Promotion of Animal Medicines.

Phil added: "The NOAH Code already goes beyond the Veterinary Medicines Regulations and is reviewed each year - this year we will be particularly looking to ensure that it fully reflects the industry's commitment to disease education and information on responsible use, particularly in relation to antimicrobial promotion. We have planned, at our Code review meeting in February, further discussions within NOAH and with the VMD to finalise how this can best be achieved.

"Importantly we must always remember that antimicrobial medicines for all animals are POM-V, meaning they have to be prescribed by a veterinary surgeon, and therefore it should be the vet who makes the decision on whether an antibiotic is needed. If such therapy is indicated, the most appropriate antibiotic for an animal or group of animals is selected by the veterinary surgeon based on the clinical signs shown, the current disease situation on the farm and in the area and where appropriate and feasible, is based on bacterial culture and sensitivity testing."

Using promotion to encourage responsible use, NOAH launched its 'Use Medicines Responsibly' campaign in 2009. A recommendation was made that members include a strap line on promotional material advising users to 'use medicines responsibly'.

NOAH was a founder member of the Responsible Use of Medicines in Agriculture Alliance (RUMA) and continues to be a strong contributor to and supporter of RUMA's communications to farmers including the antimicrobial guidelines. These guidelines are not intended to influence the veterinary surgeon's decision to prescribe but help support ways that the veterinary surgeon and farmer can work together to reduce the need to prescribe antimicrobials whilst ensuring they are used responsibly once prescribed in line with the principle of 'as little as possible but as much as necessary'.

Phil said: "Antibiotics are essential for the health and welfare of the UK's livestock population. NOAH accepts that antimicrobial resistance is a serious and growing subject of discussion for the medical and veterinary professions and we need to continue to take this matter seriously."

Bayer is highlighting a new study which, the company says, proves that a 'metaphylactic' treatment approach to coccidiosis - when the animal has been infected, but before the disease has had chance to take hold - produces the best long term results¹.

The research spanned a two year period where heifer calves on two farms that had previously experienced problems with naturally acquired coccidiosis, were divided into two groups. One group was treated with Baycox and one group remained untreated. The calves were then monitored for two years to gather the long term results following the coccidiosis treatment.

Sharon Cooksey BVSc, MRCVS, Bayer Animal Health Group Product Manager said: "The results demonstrated that treatment with Baycox at the right time significantly reduced the average age to first service by 24 days in comparison with the non-treated control group.

"Other key long term benefits following treatment included positive effects on certain fertility parameters, including overall pregnancy rate, the first service conception rate and average services per conception as well as a significant reduction in oocyst shedding in the treatment group." 

Sharon says the take home message of the new research is the paramount importance of getting treatment right at the right time, before coccidiosis develops and causes any long term implications: "The positive impact on heifer development from correct subclinical coccidiosis treatment is clear to see in this research, with the reduction of days to first service alone being a powerful reason for farmers to seek veterinary advice."

Reference

1. Veronesi F, Nisoli L, Diaferia M, Falcini R, Ficola E, Fioretti DP (2013) Influence of metaphylactic treatment with Baycox® Bovis on the reproductive performances of Fresian heifers: a preliminary study. Parasitol Res.

Bulk milk surveillance for stomach worm exposure in dairy cows has found high levels in 68% of herds, with "probable sub-clinical effects on health and production", according to Pfizer Animal Health.

Between September 2011 and March this year, 449 milk samples submitted by dairy vets and SQP animal health advisers were analysed independently for Pfizer VPS.

Pfizer VPS vet Andrew Montgomery says that stomach worm (Ostertagia ostertagi) is the species identified most often in dairy cows^1,2. and known to suppress appetite³: "Numerous trials have found a yield response to worming treatment, typically in the region of 1kg/cow/day."⁴

"At 25p/litre, this would be worth £76/cow over a 305-day lactation, or about £16,500/year in a typical 200-cow herd. Some trials have also identified improvements in reproductive performance although this remains to be proven absolutely."⁴

When test results indicate that worming is justified, Andrew recommends a moxidectin pour on treatment in the late dry period to maximise the gain over the highest yielding, early part of lactation.

The bulk milk surveillance programme is ongoing, and free Pfizer test kits are available from participating VPS animal medicine suppliers and veterinary practices.

References

1. Agneessens J et al (2000) Veterinary Parasitology 90, 83-92.
2. Borgsteede FHM et al (2000) Veterinary Parasitology 89, 287-296.
3. Forbes, AB et al (2004) Veterinary Parasitology 125, 353-364.
4. Charlier, J et al (2009) Veterinary Parasitology 164, 70-79.

Animalcare has launched Florgane, a novel, patented, long acting florfenicol 300mg/ml suspension which the company says has significant advantages over existing organic solvent-based florfenicol products on the market when used for the treatment and prevention of bovine respiratory disease (BRD).

Florgane is an aqueous, low viscosity advanced formulation, which, claims Animalcare, means that it is easier to inject even at temperatures as low as 5°C. Low temperature syringeability is important, as a large number of calves may need to be treated during colder weather at a time when the challenge from infectious agents is greatest. A syringeability study apparently demonstrated that Florgane is up to five times faster to administer when compared to the leading florfenicol non-aqueous formulation.

A paper on the treatment of naturally occurring respiratory disease with Florgane was presented recently at the British Cattle Veterinary Association (BCVA) Congress in Torquay. According to the company, the multi-centre field studies in Belgium, Germany and Italy, in over 400 cattle with bodyweights ranging between 73-180kg, demonstrated that Florgane given by a single intramuscular injection, at a 25% lower dose of 30mg/kg, is as efficacious as non-aqueous florfenicol 40mg/kg administered by subcutaneous injection, measured by treatment success and relapses.

Post mortem examination at day 27 (meat withdrawal of 37 days) confirmed that, despite being given via the intramuscular route, Florgane is well tolerated at the site of injection due to its aqueous base and physiological pH. Maximum volume per injection site is 15ml allowing calves up to 150kg to be treated.

Animalcare adds that a further advantage of Florgane is that it persists in plasma above the MICs for the three most common pathogens for significantly longer than conventional extended action 300mg/ml florfenicol solution preparations -  thereby prolonging bacterial killing time. Therefore, owing to its improved bioavailability and excellent pharmacokinetics, Florgane can be given at an easy to remember dose of 1ml per 10kg.

Tony Liepman, Marketing Manager at Animalcare said: "Using Florgane will result in faster administration, resulting in less stress for the calves and a saving in time and money for the farmer."

Florgane is presented in polypropylene 100ml and 250ml multi-dose vials with a three year shelf-life.

For more information, visit www.animalcare.co.uk

Origin (previously known as Westpoint) has announced that FarmVets SouthWest has joined the group, giving further geographical coverage to its veterinary practice network.

FarmVets SouthWest has practices at Ilminster and North Petherton in Somerset and Honiton in Devon.

Eoghan McAlonan, a director of the practice, said: "We are delighted to be joining Origin. The Origin group delivers the highest standards in veterinary services to UK agriculture, and we will bring our farmer friendly services to further enhance the groups activities".

In turn Origin says it plans to bring the wide benefits of group membership, including lab services, dairy consultancy and paraprofessional services, to further enhance the high level of service the vet team at Farmvets SouthWest provide to producers in Somerset and Devon.

Jon Mouncey, Managing Director of Westpoint Farmvets, said: "Working alongside our other Origin practices in the South West region, we can now offer all livestock producers our advanced services, ensuring their stock receive the very best in veterinary care. Our group offers a unique approach to integrated veterinary services and by applying the latest technology and research we ensure that animal health and welfare is optimised, delivering real value for our clients in a challenging agricultural climate."

Ceva Animal Health has announced that Bluevac-3, its new bluetongue (BTV-3) vaccine, will be available from mid-October.

Bluevac-3 is an inactivated injectable vaccine indicated for the active immunisation against BTV-3 for use in sheep and cattle. 

Ceva says it reduces viraemia, prevents mortality and reduces the clinical signs of BTV-3 in sheep and reduces viraemia in cattle.

In sheep, Bluevac-3 can be administered from two months of age and two doses of 2ml should be administered subcutaneously three weeks apart.

In cattle, the vaccine can be administered from two months of age and two doses of 4ml should be administered three weeks apart.

Onset of immunity occurs 21 days/three weeks after completion of primary vaccination in cattle and sheep.

The vaccine can be used in pregnancy in cows and ewes.

No negative impact on milk-yield after using the vaccine in lactating ewes and cows is expected.

Ceva developed the new vaccine in partnership with vaccine manufacturer CZV Vaccines and launched it in Europe early in the summer, to mitigate the impact of the disease already experienced in the Netherlands, Belgium, and Germany.

Craig Wright, ruminant business unit director at Ceva Animal Health, said: “In co-operation with our partner, CZV Vaccines, we have worked tirelessly to bring Bluevac-3 to the UK to help fight bluetongue which has the potential to cause severe financial loss to farmers. 

"The availability of an effective vaccine is an essential tool to help suppress future outbreaks by reducing viraemia, preventing mortality and reducing the clinical signs of BTV-3.”

Licences to allow the use of the new vaccine will either be geographically targeted general licences, initially in high risk counties as part of a phased approach, or specific licences which can be applied for through APHA.

General licencing will be subject to risk assessment.

https://www.gov.uk/government/publications/summary-of-product-characteristics-for-bluevac-3-btv-3-vaccine-in-the-uk. 

40% of Brits are more likely to trust their vet's advice above that of other health practitioners such as GPs, dentists and opticians, according to research announced today by Petplan.

The younger generation are the least trusting in their human healthcare providers with a resounding majority of those surveyed in the 16 to 24 age group saying they are most likely to trust their vet's advice over their doctor's.

Nationally, nearly four out of ten pet owners put more faith in vets than doctors, rising to 7 in 10 in some parts of the country.

Talking of which, my mother needs a new hip. Any of you up for it?

The Society for Practising Veterinary Surgeons (SPVS) has published its 2015 Fee Survey, which has revealed an increasing divergence between fees charged for routine and unroutine procedures in small animal practice.

SPVS says that small animal practices accounted for the largest proportion of responses to its survey, and that 75.9% of them had increased their fees during the last 12 months. When comparing a 'bundle' price comprising a kitten vaccination course, puppy vaccination course, cat spay, dog spay and consultation, the increase was 4.09%. However SPVS notes that this increase may be artificially low, as it relates to the sort of procedures that are regularly quoted and may therefore be constrained by the marketplace.

Perhaps more revealingly, whilst routine procedures such as vaccination had risen 3.3%, non routine procedures had risen by considerably more: pyometras were up 15.6%, cat dentals were up 17.5% and out-of-hours callouts  were up 18.6%.

Equine fees showed an overall drop of 3.5% on the bundle price comprising initial routine examination, five-stage PPE, routine dental examination and float, a colic examination and the cost of sedation / waiting. Although many of the individual equine procedures showed a fee decrease, 79% of equine practices reported that they had increased fees over the past year. The largest decrease in equine fees was for sedating a horse and waiting while the horse was clipped or treated by an equine dental technician, with the fee charged being 12.5% less than last year and ranging from £12.50 to £93.82. Conversely, conducting an ultrasound scan of a mare for pregnancy had increased by 17.3% and ranged from £20 to £62.36.

For large animal vets, the fees are more tightly constrained by the commercial realities of farming and the range of fees quoted tends to be lower. This year, the overall price rise for the bundle of fees comprising routine calving, foot trimming, elective Caesarean and hourly rates for fertility work and herd health schemes was 4.1%. However, only 47.8% of large animal practices reported an increase in fees charged over the last twelve months. The largest increase reported was for paring the hind feet of a cow without sedation, which was up 24.4% and ranged in price from £19 to £70, while issuing a prescription to a farm animal client had decreased by 1.6% and ranged in price from 0 to £48.

Nick Stuart, SPVS president said: "We all know the industry is facing real challenges and this is reflected in the fee survey, with equine practices in particular decreasing many of their prices on last year. However the survey also shows that the fees vets charge vary widely, particularly in the small animal sector. While some of this can be accounted for by differing overheads, it does provide a fascinating insight into the various financial models that exist and challenges practice owners to review how they construct their fees. It also suggests that there is scope for practices to grow their profitability and understanding the market will help them with this.

"We have a new benchmarking service from Veterinary Insights that will help practices to set more accurate fee levels and we will be developing our fee survey further so that it dovetails with this service. I would urge practices to join SPVS and access the invaluable data we produce to help them grow their businesses."

For more information, a copy of the survey, or to join SPVS visit www.spvs.org.uk

To celebrate the launch of its brand new keep reproduction simple advertisement campaign, CEVA Animal Health is giving British Cattle Veterinary Association (BCVA) Congress delegates the chance to win an iPod by entering a special spot the sperm competition. 

BCVA Congress runs from 26-28 November 2009 in Southport. Delegates just need to spot five sperm lurking in the banner-sized cartoon for CEVA's GnRH product Ovarelin^®. The correct answers will be entered into a draw to win an iPod.

The company says its new ad campaign brings together a series of cartoons with a clever play on words to highlight the importance of a simple protocol for success with reproduction. You can follow this irresistibull series in the farm media throughout the autumn. 

For further information contact your local CEVA representative or CEVA Animal Health Ltd, 90 The Broadway, Chesham, Bucks, HP5 1EG, www.ceva.uk.com

MSD Animal Health has launched Porcilis Lawsonia, the first intramuscular pig vaccine to control Lawsonia intracellularis, the bacteria which causes Ileitis.

MSD says Lawsonia intracellularis is found on many finishing farms throughout the UK, and can affect weight gains, feed conversion ratios (FCR) and lead to increased mortality. 

The new vaccine means that if piglets are vaccinated at three weeks, they will be protected against the bacteria from seven weeks. 

Rubén Del Pozo Sacristán, technical manager for pigs at MSD Animal Health, said "Lawsonia intracellularis is present on most UK farms and can hamper a farm’s true potential as it spreads rapidly in faeces and on people or rodents, but symptoms can be hard to identify, as they’re often similar to many other diseases.

"Acute forms are often noticeable with symptoms such as diarrhoea or an increase in mortality, but the subclinical form, which is most common, can be hard to identify. Diarrhoea is not always present and often indicators are an increase in FCR and a reduction in weight gain leading to variation in pig performance, but this is similar to many other health issues.

"Administering an intramuscular vaccination will ensure every animal receives the correct dose, compared to other administrative routes. Porcilis Lawsonia can help reduce the clinical signs, production losses and mortality caused by Ileitis."

For more information on Porcilis Lawsonia, refer to the SPC sheet.

The Animal Medicines Distributors Association (AHDA) and the Animal Medicines Training Regulatory Authority (AMTRA) have both come out against the BVA's call for all anthelmintic medicines to be reclassified as POM-V, which would prevent them being prescribed by Suitably Qualified Persons (SQP).

Ian Scott, Secretary General of AHDA, said that instead of launching an attack on SQPs, the BVA should be working with them and animal owners to tackle anthelmintic resistance: "The BVA has written to the VMD to ask that all anthemintics be classified to POM-V only. This will monopolise the supply and distribution of anthelmintics for vets only. It effectively places the blame for anthelmintic resistance squarely on SQPs.

"An attempt by BVA to create a division between vets and SQPs demonstrates that the BVA is out of touch with its members.

"Both prescribing channels must work together to tackle the problem and AHDA has been working hard with vets at national and local level to ensure customers receive consistent, high quality, up-to-date and relevant advice from both channels.

"What is worrying is that the BVA attack also infers that farmer producers and equine owners are incapable of making decisions that not only affect their livelihood but cast doubt on their ability to care for their animals' welfare."

Meanwhile, Stephen Dawson, Secretary General of AMTRA said: "The large majority of SQPs deal with parasite control on a daily basis, having trained and been examined to a syllabus developed with BVA input. SQPs have to undertake compulsory continuing professional development, the majority of which includes good practice in parasite control. Therefore AMTRA has every confidence that qualified SQPs have excellent knowledge of parasitology to advise their clients on the correct choice and use of anthelmintics.

"It is important to recognise the hard work, knowledge and dedication of thousands of SQPs throughout the UK. The implication of what BVA say is that they are laying a proportion of the blame for resistance to these medicines at the door of SQPs. But the evidence isn't there: countries in Europe and elsewhere with different prescription systems, mainly though vet-only channels, still have major resistance problems. Prescription of antimicrobials by veterinary surgeons hasn't prevented concerns about prescribing practices and developing resistance. The key point is good advice from the prescriber and how they are then used in practice, rather than who prescribes them. The challenge for us all is not just to seek excellence in prescribing but also in usage on farm, something SQPs are ideally placed to do with their frequent farmer contact.

"I would urge all parties to work in partnership to ensure that best practice in prescription and use is followed by all prescribers and users. It is up to all prescribers to act responsibly, but to single out one group over another is unjustified. A pseudo-monopoly by vets on supply would do nothing to help farmers in difficult times."

Mr Dawson also expressed doubts about permanent POM-V status for new livestock anthelmintics: "While we fully support VMD's and VPC's need to be sure that the risk associated with wider availability of a new product is low, AMTRA considers that the current division in distribution classes and consequent low uptake of the newer products means that the much bigger risk is that widespread reliance on the three aging classes may be followed by reliance on just the two new classes when the older classes become unusable. Much better to have responsible prescription of all five classes now, by appropriately trained SQPs, vets and pharmacists, to ensure that there is a prospect of long term availability of effective parasite control."